Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on Capital EmployedReturn on Invested CapitalTimes Interest Earned

Lifecore Biomedical, Inc. \De\ (LFCR) EBITDA Margin (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 16 years of EBITDA Margin data on record, last reported at 14.62% in Q2 2025.

  • For Q2 2025, EBITDA Margin rose 894.0% year-over-year to 14.62%; the TTM value through May 2025 reached 13.38%, down 2995.0%, while the annual FY2025 figure was 13.38%, 649.0% down from the prior year.
  • EBITDA Margin reached 14.62% in Q2 2025 per LFCR's latest filing, up from 25.68% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 84.59% in Q2 2022 and bottomed at 137.58% in Q1 2023.
  • Average EBITDA Margin over 5 years is 9.81%, with a median of 12.09% recorded in 2022.
  • Peak YoY movement for EBITDA Margin: plummeted -11942bps in 2023, then skyrocketed 18136bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 28.58% in 2021, then plummeted by -300bps to 57.26% in 2022, then soared by 182bps to 47.16% in 2023, then tumbled by -113bps to 6.02% in 2024, then surged by 343bps to 14.62% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 14.62% in Q2 2025, 25.68% in Q1 2025, and 6.02% in Q4 2024.